In a recent phase 1–2 trial, Selinexor was tested in combination with docetaxel in previously treated, advanced KRAS-mutant NSCLC patients (n = 40): of 32 patients evaluated for efficacy, 7 (22%) had a PR, and 18 (56%) had an SD, with a median PFS of 4.1 months and a median OS of 7.1 months, with no difference based on the various KRAS mutation types.265 The XPO1 inhibitor selinexor is currently approved in relapsed/refractory (R/R) multiple myeloma in combination with bortezomib and dexamethasone and as a monotherapy for patients with R/R diffuse large B-cell lymphoma.266,267. Here, KRAS is linked to AL amyloidosis.